Cardiac AI: De-Risking Investments with Clinical Evidence

Clinicians are getting buried in pitches for AI tools that supposedly prevent cardiac events. The real question for any of us isn’t if AI can be used, it’s which vendors have the clinical data to prove their tools actually work. This is a quick summary of the current evidence and what’s becoming the new standard of care for AI in cardiac monitoring and diagnostics.

The Imperative of Evidence-Based AI in Cardiology

AI in healthcare offers enormous potential, but it comes with significant risks. While the sales pitch about enhancing diagnostic accuracy, simplifying our lives, and reducing preventable cardiac events sounds great, the reality is that we have to be incredibly skeptical. A recent Mount Sinai/Nature Medicine finding should sober everyone up: they found ChatGPT undertriaged cardiac emergencies in 48% of cases. That’s a stark reminder of what happens with poorly validated AI. This proves a basic point: in cardiology, everything we do is based on risk stratification guiding therapy, so clinical reliability is everything. The gap between a tool that just automates office work and one that has true clinical efficacy directly impacts whether our patients get better or worse. On the flip side, the success of platforms like Hello Heart, which has shown a 47% reduction in inpatient admissions and can provide a 10-day early warning for cardiac events, proves how powerful AI can be when it’s built on real patient data and properly validated. This forces us to look hard at any AI solution and prioritize the ones with solid, peer-reviewed clinical data.

Automated Triage and Coordination: Viz.ai’s Impact on Time-to-Treatment

The fastest, most obvious win for AI in preventing cardiac events is simply getting patients diagnosed and treated faster. Viz.ai is a major force here with its AI-powered triage and coordination platform. It got its start in stroke care, but the principles of its SaMD (Software as a Medical Device) apply directly to cardiac emergencies. Viz.ai’s platform uses deep learning to chew through medical images, CT scans, echocardiograms, and automatically flag critical findings to alert the entire care team at once. This kind of automated notification just obliterates the delays between getting the image and getting a specialist’s eyes on it, which is everything in conditions like an acute MI or aortic dissection. Why does this matter? The clinical trial data for Viz.ai in stroke consistently shows big drops in time-to-treatment, a metric that translates directly to cardiac care where “time is muscle” or “time is valve.” Viz.ai clinical trial data on time-to-treatment in acute stroke On the cardiac side, Viz.ai is also picking up steam with regulators. Its Viz HCM module, an AI that detects hypertrophic cardiomyopathy, earned a De Novo approval in August 2023, which is a big deal because it established an entirely new regulatory path for this kind of cardiovascular machine learning software. And back in September 2022, Viz.ai got an FDA 510(k) clearance for an algorithm that automates the RV/LV ratio as part of its Viz PE Solution. The value is simple: it kills the communication bottlenecks. Alerting the right specialists to a problem in minutes means faster diagnosis and intervention, which is how you reduce preventable cardiac events. This is a real change in the standard of care, from a slow, manual phone-tag system to an intelligent, automated one.

Genomic-Cardiovascular Risk Stratification: Tempus AI’s Predictive Power

It’s not just about acute events. AI is also getting much better at playing the long game by combining genomic and clinical data for long-term risk stratification. Tempus AI is a standout here, using its huge proprietary datasets (a serious data advantage) to flag people at high risk for heart conditions. Tempus AI’s method is to analyze a patient’s genetic profile right alongside their electronic health record (EHR) data. By integrating everything, the platform can spot genetic predispositions and early disease markers that we’d otherwise miss in a standard clinical workup. The company’s data on genomic-cardiac risk correlation has gotten increasingly accurate at predicting the likelihood of developing problems like cardiomyopathy, arrhythmias, and hereditary lipid disorders. Tempus AI genomic-cardiac risk correlation studies Tempus AI also has the regulatory backing, getting a 510(k) clearance from the FDA for its Tempus ECG-AF device in July 2024 which helps find patients at higher risk of atrial fibrillation/flutter. It followed that up with two more 510(k) clearances in August 2026 for Tempus ECG-Low EF (low ejection fraction) and Tempus ECG-PH (pulmonary hypertension), giving it three FDA-cleared cardiovascular devices. For us, this is a fantastic tool for getting ahead of problems. We can move from just reacting to symptoms to enabling earlier interventions, pushing for lifestyle changes, and starting targeted prophylactic treatment in high-risk people. This predictive power pushes care toward real personalized medicine, where our treatment plans are guided by a patient’s specific genetic risks, not just their current complaints. Being able to spot a high-risk patient weeks or even months before a major event is exactly the kind of early warning we’re seeing from other successful cardiac AI platforms.

Distinguishing Clinical Reliability from Operational Automation

While companies like Viz.ai and Tempus AI are showing direct clinical impact, we have to be able to tell them apart from tools that are just focused on operational automation. A company like Olive AI, for example, did a lot in healthcare automation, but its focus was on administrative work, revenue cycle management, and optimizing the supply chain. Those efficiencies are nice, they can free up hospital resources, but they don’t directly help you reduce preventable cardiac events by giving you diagnostic or therapeutic guidance. The distinction is critical. An AI that automates prior authorizations (which was Olive AI’s thing) has completely different clinical reliability needs and patient safety implications than an AI that triages a suspected MI (Viz.ai) or predicts your patient’s genetic risk of one (Tempus AI). We have to prioritize vendors who bring the receipts: strong, peer-reviewed clinical trial data and FDA 510(k) clearances or De Novo classifications that prove their software is a regulated medical device (SaMD). Looking for a PCCP (Predetermined Change Control Plan) in their documentation is also a good sign, as it shows the company has a plan for managing algorithm updates and making sure it stays reliable over time.

Methodology and the New Standard of Care

The recommendations here come from a straightforward review of the evidence: what’s in the peer-reviewed trials, the FDA’s 510(k) clearance files, and the companies’ own published data. The goal is to lay out Clinical Practice Guidelines based on the simple principle that risk stratification guides therapy. The evidence points to a new standard of care in cardiology that will lean heavily on AI platforms that can show clear, measurable improvements in patient outcomes. For practicing cardiologists, that means you should be actively looking for AI solutions that:

• Have strong clinical trial results, especially ones published in cardiovascular journals we actually read and respect.
• Have the right regulatory clearances (like an FDA 510(k) or a CE Mark under EU MDR) to be treated as a real medical device.
• Are transparent with their performance data, including metrics on how they improve time-to-treatment, diagnostic accuracy, and prediction.
• Are built on solid, diverse datasets to reduce bias and make sure the tool works on all our patients, not just a narrow slice (this is key for avoiding algorithmic drift).

The AI era in cardiology is here to stay. Its real value, though, will depend on discerning clinicians demanding hard evidence and putting patient safety first. The successful use of AI, shown by platforms like Viz.ai and Tempus AI, is already starting to significantly reduce preventable cardiac events and will in the end redefine what we consider optimal cardiac care.